10 Jun 2022
Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab in Heavily Pretreated Patients with Multiple Myeloma
Author: admintech | Filed under: Press ReleaseUpdated results for talquetamab monotherapy and in combination with daratumumab highlighted in oral presentations at the 2022 EHA Annual Congress VIENNA, June 10, 2022 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the Phase 1…